https://www.selleckchem.com/products/cm-4620.html
Our data are the first to show a clinical benefit from targeted treatment with ROS1 TKI in a cancer patient with a thus far undescribed ROS1 point mutation without a concomitant ROS1 rearrangement. Furthermore, they indicate that ROS1 could be an oncogenic driver in pancreatic cancer. This subgroup could be eligible for targeted treatments, which may contribute to the urgently needed improvement in patient outcome. Our data are the first to show a clinical benefit from targeted treatment with ROS1 TKI in a cancer patient with a thus far
Like
Comment
Share
